These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29556418)
41. Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. Emery P; van Hoogstraten H; Thangavelu K; Mangan E; St John G; Verschueren P ACR Open Rheumatol; 2020 Nov; 2(11):672-680. PubMed ID: 33164349 [TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B; Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929 [TBL] [Abstract][Full Text] [Related]
43. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854 [TBL] [Abstract][Full Text] [Related]
44. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
45. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Fleischmann R; Genovese MC; Lin Y; St John G; van der Heijde D; Wang S; Gomez-Reino JJ; Maldonado-Cocco JA; Stanislav M; Kivitz AJ; Burmester GR Rheumatology (Oxford); 2020 Feb; 59(2):292-302. PubMed ID: 31312844 [TBL] [Abstract][Full Text] [Related]
46. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428 [TBL] [Abstract][Full Text] [Related]
47. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816 [TBL] [Abstract][Full Text] [Related]
48. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216 [TBL] [Abstract][Full Text] [Related]
49. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921 [TBL] [Abstract][Full Text] [Related]
50. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. McCarty D; Robinson A Ther Adv Musculoskelet Dis; 2018 Mar; 10(3):61-67. PubMed ID: 29492111 [TBL] [Abstract][Full Text] [Related]
52. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Siebuhr AS; Bay-Jensen AC; Leeming DJ; Plat A; Byrjalsen I; Christiansen C; van de Heijde D; Karsdal MA Arthritis Res Ther; 2013 Aug; 15(4):R86. PubMed ID: 23945134 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis. Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429 [TBL] [Abstract][Full Text] [Related]
54. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Mueller RB; Graninger W; Sidiropoulos P; Goger C; von Kempis J Clin Rheumatol; 2017 Oct; 36(10):2187-2192. PubMed ID: 28776300 [TBL] [Abstract][Full Text] [Related]
55. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Romas E; Gillespie MT; Martin TJ Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640 [TBL] [Abstract][Full Text] [Related]
56. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Bugatti S; Manzo A; Vitolo B; Benaglio F; Binda E; Scarabelli M; Humby F; Caporali R; Pitzalis C; Montecucco C Rheumatology (Oxford); 2014 Oct; 53(10):1886-95. PubMed ID: 24764267 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514 [TBL] [Abstract][Full Text] [Related]
58. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. Schiff M; Combe B; Dörner T; Kremer JM; Huizinga TW; Veenhuizen M; Gill A; Komocsar W; Berclaz PY; Ortmann R; Lee C RMD Open; 2015; 1(1):e000037. PubMed ID: 26535134 [TBL] [Abstract][Full Text] [Related]